This content is from: Portfolio GMO Is Feeling Pain Reminiscent of the Late 1990s The patience of GMO’s clients is “wearing thin,” according to Ben Inker, the firm’s head of asset allocation. By Christine Idzelis October 10, 2019
This content is from: Corner Office CircleUp Hires GMO Partner as First CIO in Quant Push The San Francisco firm is bringing quantitative investing to private markets. By Christine Idzelis August 08, 2019
This content is from: Portfolio GMO: Your Portfolio Obsession Is Forcing Bad Calls A simple analysis of historical returns is leading investors to build portfolios that solve the “wrong problem,” according to GMO’s letter to clients. By Christine Idzelis May 09, 2019
This content is from: Portfolio GMO Says Emerging Markets Stocks Will Trounce U.S. Equities The value investing firm is forecasting losses for U.S. stocks over the next seven years. By Christine Idzelis August 22, 2019
This content is from: Portfolio Jeremy Grantham Says Investors Should Be ‘Intrigued’ by This Strategy GMO co-founder Grantham sees profit in battling an existential threat. By Christine Idzelis April 22, 2019
This content is from: Portfolio GMO Pitches a Curveball At a firm famous for bearish value investing, fund manager Tom Hancock argues for a surprising strategy. By Christine Idzelis January 02, 2019
Sponsored Adapting to Rapid Change and Finding Opportunities in Fixed Income Sponsored by iShares December 04, 2019
